Antichagasic Activity of Komaroviquinone Is Due to Generation of Reactive Oxygen Species Catalyzed by *Trypanosoma cruzi* Old Yellow Enzyme

Nahoko Uchiyama,1,7 Zakayi Kabututu,2 Bruno K. Kubata,3 Fumiyuki Kiuchi,4 Michiho Ito,1 Junko Nakajima-Shimada,5 Takashi Aoki,5 Kei Ohkubo,6 Shunichi Fukuzumi,6 Samuel K. Martin,3 Gisho Honda,1 and Yoshihiro Urade2*

Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan; Department of Molecular Behavioral Biology, Osaka Bioscience Institute, Osaka 565-0874, Japan; United States Army Medical Research Unit-Kenya, Unit 64109, APO AE 09831-64109, Kenya; Tsukuba Medicinal Plant Research Station, National Institute of Health Sciences, Tsukuba 305-0843, Japan; Department of Molecular and Cellular Parasitology, Juntendo University School of Medicine, Tokyo 113-8421, Japan; Department of Material and Life Science, Graduate School of Engineering, Osaka University, SORST, JST, Osaka 565-0871, Japan; and Faculty of Pharmaceutical Sciences, Doshisha Women’s College of Liberal Arts, Kyoto 610-0395, Japan

Received 14 June 2005/Returned for modification 22 July 2005/Accepted 20 September 2005

A novel potent trypanocidal diterpene, komaroviquinone, was reduced by *Trypanosoma cruzi* old yellow enzyme (ToYE) to its semiquinone radical. The reductase activity in trypanosome lysates was completely immunoabsorbed by anti-ToYE antibody. Since ToYE is expressed throughout the *T. cruzi* life cycle, komaroviquinone is an interesting candidate for developing new antichagasic drugs.

*Trypanosoma cruzi* is a parasitic protozoan transmitted to mammalian hosts by blood-sucking triatomine bugs (12). Infections by *T. cruzi*, known as Chagas’ disease, pose a major public health problem in endemic countries in Central and South America (20) and result in a life-threatening, acute, and/or chronic disease with severe complications. This situation is worsened by the lack of effective vaccines and undesirable side effects of antichagasic drugs in use, such as nifurtimox and benznidazole, in addition to the emergence of parasite resistance to these drugs. Therefore, developing new chemotherapeutic agents becomes an urgent need.

Our search for trypanocidal compounds by screening traditional medicinal plants used in Uzbekistan led to the isolation of four diterpenes from *Dracocephalum komarovi* Lipsky (18, 19). Among those diterpene compounds, komaroviquinone displayed the strongest trypanocidal activity against epimastigotes, the replicative form in the insect vector of *T. cruzi* (18, 19). Thus, we decided to study the trypanocidal properties of komaroviquinone against trypanomastigotes, the nondividing and infective form circulating in the blood, and amastigotes, the intracellular replicative form within the mammalian host, of *T. cruzi*.

Epimastigotes, trypanomastigotes, and amastigotes of *T. cruzi* (Tulahuen strain) were cultivated as reported previously (8, 11, 15). Trypanocidal activity against epimastigotes was determined by incubation with propidium iodide solution (5 μg/ml in phosphate-buffered saline [PBS]), followed by FACScan cytometry (Becton Dickinson). The trypanocidal activity against trypanomastigotes was measured after the incubation of parasite cells (2 × 10⁶ to 3 × 10⁶ cells/ml of Eagle minimum essential medium) with test compounds for 24 h at 37°C. Viability of trypomastigotes were counted as described previously (11). The cytotoxicity of compounds against human HeLa and KB 3-1 cell lines was examined by a modified MTT [3-(4,5-dimethyl-2-thiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay (10). HeLa cell infection activity was determined by infection with trypomastigotes that subsequently differentiated into amastigotes within HeLa cells (11, 12).

Trypanocidal activity of komaroviquinone is summarized in Table 1 and Fig. 1. Komaroviquinone inhibited the survival of epimastigotes of *T. cruzi* in a concentration-dependent manner from 0.1 to 10 μM, showing a 50% inhibitory concentration (IC₅₀) value of 1 μM which was 10-, 30-, and 4-fold lower than those of reference trypanocidal agents nifurtimox, benznidazole, and menadione, respectively. Komaroviquinone inhibited the survival of trypomastigotes more potently than that of epimastigotes in a concentration-dependent manner from 3 to 30 nM, displaying an IC₅₀ value of 9 nM, which was 100-fold lower than that of epimastigotes. The inhibition of HeLa cell infection with trypomastigotes by komaroviquinone showed the same IC₅₀ value (9 nM) as that of the survival inhibition, which was 33-, 190-, and 330-fold lower than that of nifurtimox, benznidazole, and menadione, respectively. However, komaroviquinone at its highest concentration (3 μM) did not inhibit the intracellular growth of amastigotes within HeLa cells under our experimental conditions (data not shown). Furthermore, komaroviquinone showed low toxicities against human HeLa and KB 3-1 cells, as indicated by IC₅₀ values of 20 and 17 μM, respectively. The selective toxicity of komaroviquinone between the parasite and host cells was calculated to be about 2,200, which is 6.5-, 38-, and 190-fold higher than that of nifurtimox, benznidazole, and menadione, respectively. These results clearly indicate that komaroviquinone is the most po-
tent and selective trypanocidal compound among the tested drugs. This makes komaroviquinone a good candidate for drug development. Since blood transfusion is the second route of transmission of Chagas' disease, with the prevalence of infected blood donors varying from 0.10% to 62.1% in endemic areas of Latin America (9), trypanocidal agents such as gentian violet are used in blood banks to clear trypomastigotes from donated blood. Komaroviquinone, which shows an IC50 value for trypomastigotes 4 orders of magnitude lower than that of gentian violet (245 M and 245 M) (2), can be considered as a valuable tool for such use.

Trypanocidal activity of several types of natural quinones has been partly attributed to reactive oxygen species generated by the reduction of drugs (4, 14). We have previously reported that T. cruzi old yellow enzyme (TcOYE) is involved in the generation of reactive oxygen species (6) which have been shown to kill parasites (5, 21). We therefore tested whether TcOYE catalyzes the reduction of komaroviquinone. TcOYE was heterologously expressed in Escherichia coli and purified to apparent homogeneity as described previously (6). Under anaerobic conditions, komaroviquinone was reduced by recombinant TcOYE in the presence of NADPH. The Km and V max values of TcOYE for the reduction of komaroviquinone (30 M and 360 nmol/min/mg, respectively) were in the same range as those for the reduction of nifurtimox (19 M and 350 nmol/min/mg, respectively) and menadione (13 M and 420 nmol/min/mg, respectively). However, these agents showed significantly different values of IC50 for the inhibition of HeLa cell infection with trypomastigotes (Table 1). This discrepancy may be due to differences in cell membrane permeability to agents and/or to the presence of agent-inactivating factors in the parasite cell.

Electron spin resonance (ESR) analysis (6) revealed that a signal corresponding to a semiquinone free radical was observed during the incubation of komaroviquinone with recombinant TcOYE in the presence of NADPH under anaerobic conditions (Fig. 2A). The semiquinone radical in turn reduced O2 to the superoxide anion radical O2 when conditions were switched to aerobic mode (Fig. 2B). As expected, the semiquinone anion radical was also generated upon incubation of T. cruzi epimastigote lysates with komaroviquinone under anaerobic conditions (data not shown). Thus, TcOYE-catalyzed reduction of komaroviquinone turns out to be a one-electron transfer process in which komaroviquinone is continuously re-

TABLE 1. Inhibitory effect (IC50 in M) and selective toxicity of komaroviquinone and trypanocidal agents on T. cruzi and mammalian cells

<table>
<thead>
<tr>
<th>Effect or toxicity</th>
<th>Komaroviquinone</th>
<th>Nifurtimox</th>
<th>Benznidazole</th>
<th>Menadione</th>
</tr>
</thead>
<tbody>
<tr>
<td>Survival of epimastigotes</td>
<td>1.0</td>
<td>10.0a</td>
<td>30.0b</td>
<td>4.0</td>
</tr>
<tr>
<td>Survival of trypomastigotes</td>
<td>0.009</td>
<td>0.3</td>
<td>1.7</td>
<td>3.0</td>
</tr>
<tr>
<td>Infection of HeLa cells with trypomastigotes</td>
<td>0.009</td>
<td>103.0c</td>
<td>&gt;100</td>
<td>38.0d</td>
</tr>
<tr>
<td>Growth of HeLa cells</td>
<td>20.0</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>52.0d</td>
</tr>
<tr>
<td>Growth of KB 3-1 cells</td>
<td>17.0</td>
<td>343</td>
<td>&gt;59</td>
<td>13</td>
</tr>
<tr>
<td>Selective toxicity</td>
<td>2,222</td>
<td>343</td>
<td>&gt;59</td>
<td>13</td>
</tr>
</tbody>
</table>

a See reference 7.
b See reference 2.
c See reference 1.
d See reference 13.
e Ratio between IC50 for inhibition of growth of HeLa cells and inhibition of infection of HeLa cells with trypomastigotes. Values are averages of two separate determinations.

FIG. 1. Concentration-dependent inhibition of epimastigote survival by komaroviquinone and menadione and inhibition of trypomastigote survival by komaroviquinone. Parasite cell count in the untreated control culture was considered 100%. Values are averages of two separate determinations.

FIG. 2. (A) ESR spectrum of semiquinone anion radical generated after incubation of komaroviquinone with TcOYE under anaerobic conditions with a spectral fission factor (g) value of 2.0042. (B) ESR spectrum of O2 g = 2.09 and g = 2.005 was measured at 155°C and formed under aerobic conditions in the reaction of semiquinone anion radical of komaroviquinone with O2. (C) Redox-cycling scheme showing the one-electron reduction of komaroviquinone catalyzed by TcOYE.
generated through a redox-cycling system (Fig. 2C). These data suggest that reactive oxygen species, known for their damaging actions on cellular components (3, 5), are involved in the trypanocidal mechanism of komaroviquinone.

When we incubated hypotonic lysates of *T. cruzi* epimastigotes with various amounts of polyclonal anti-TcOYE antibody (6), the komaroviquinone reductase activity decreased in a dose-dependent manner and was almost completely immunoadsorbed by excess amounts of the antibody (Fig. 3A). Western blot analysis with the anti-TcOYE antibody revealed that TcOYE in the supernatant of *T. cruzi* lysates was precipitated by the antibody in a dose-dependent fashion until its complete removal (Fig. 3B). These results clearly indicate that TcOYE is the main source of komaroviquinone reductase activity in *T. cruzi*, thus implying that trypanocidal activity of komaroviquinone is specifically due to its reduction by the parasite enzyme TcOYE.

We then investigated the expression of TcOYE in different stages of the *T. cruzi* life cycle. The three stages of parasite cells were fixed with 10% formaldehyde in PBS for 30 min at room temperature, washed with PBS, and incubated with rabbit polyclonal anti-TcOYE antibody (1:500 dilution) followed with rhodamine-labeled anti-rabbit immunoglobulin G (1:100 dilution; Kirkegaard & Perry Laboratories) for 1 h each at room temperature. After nuclear staining with Hoechst 33342 (1:5,000 dilution; Wako Pure Chemical Industries) for 10 min at room temperature, the immunostained cells were observed under a fluorescence microscope (Zeiss). Positive immunofluorescence for TcOYE was found in the cytoplasmic area of epimastigotes (Fig. 3C, panel I), trypomastigotes (Fig. 3C, panel II), and amastigotes (Fig. 3C, panel III). This finding was further confirmed by Western blotting, which detected a 42-kDa band of similar intensity in the lysates of all stages of *T. cruzi* (Fig. 3C, panel IV). These data are in agreement with the cytosolic localization of TcOYE in *T. cruzi* epimastigotes (6).

Although TcOYE is expressed at similar levels in all stages of the parasite life cycle, IC₅₀ values of komaroviquinone for the inhibition of *T. cruzi* viability significantly varied from stage to stage. Unfortunately, komaroviquinone was devoid of any inhibitory effect on intracellular replication of amastigotes within HeLa cells. These discrepancies may be explained either by the inability of these cells to take up the compound or by the rapid degradation of komaroviquinone into inactive metabolites after its incorporation in HeLa cells. Indeed, Torres-Mendoza et al. (16, 17) have shown some diterpenes from *Myrosernum frutescens* to be more active against the extracellular than intracellular form of *T. cruzi*.

Here, we have shown that komaroviquinone is a potent trypanocidal agent against trypomastigotes of *T. cruzi*. To improve its pharmacological parameters, we intend to use komaroviquinone as a lead compound for the rational design of structurally improved derivatives with the ability of remaining stable in the host cell environment, thus inhibiting amastigote cell replication. Future assays of komaroviquinone on animal...
models of *T. cruzi* infection will determine the biological activity of komaroviquinone under pathophysiological conditions.

We thank K. Nagamune and S. Tamura for their assistance in cytotoxicity studies. This work was supported in part by a Japan Society for the Promotion of Science postdoctoral fellowship (no. 02271) to Z.K. and a grant-in-aid (no. 16205020) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan, to K.O. and S.F.

REFERENCES


